Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2018

View Archived Issues

Enrollment ongoing in phase II/III trial of indoximod plus pembrolizumab or nivolumab in melanoma

Roswell Park Cancer Institute and NCI begin phase I trial of sirolimus plus vaccine therapy

Tosk set to begin proof-of-concept studies of TK-90

Generation Bio launches

Rocket and Inotek complete merger

Gossamer Bio launches with USD 100 million financing

Jiangsu Hengrui Medicine grants SHR-0302 rights to Arcutis for dermatology disorders

Stemline presents phase I/II data on SL-401 for myeloproliferative neoplasms

EMA gives orphan drug designation to Spruce Biosciences' SPR-001

Peregrine Pharmaceuticals changes name to Avid Bioservices

Momenta Pharmaceuticals announces topline data from phase I study of M-281

Northwestern University describes novel nitric oxide synthase inhibitors

MAKO study of squalamine with Lucentis in wet AMD misses primary endpoint

Institute of Organic Chemistry and Biochemistry and others patent 17-beta-HSD inhibitors

EMA accepts Evenity MAA in osteoporosis

New farnesoid X receptor modulators identified at Gilead

Alnylam and Sanofi to restructure RNAi therapeutics alliance

Rice University presents novel thailanstatin A derivatives

Cadent Therapeutics discovers new potassium channel modulators

FDA approves sBLA for Amgen's Xgeva

Final draft guidance by U.K.'s NICE recommends use of Strimvelis for ADA-SCID

Celgene agrees to acquire Impact Biomedicines

Rebiotix announces results of analysis of microbiome drug candidates

ADAR1-targeted therapy could ameliorate multiple myeloma patient outcomes

Takeda and Denali enter option and collaboration agreement in neurodegenerative diseases

Kala announces NDA acceptance for KPI-121 1%, phase III data for KPI-121 0.25%

Experiments reveal the potential of antibiotics for the treatment for colorectal cancer

Enanta conducts first-in-human study of EDP-938

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...